Drug Trial Radar · NCT07357727
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
460
Planned (sponsor's estimate)
Start
May 27, 2026
Primary completion
May 17, 2028
Study completion Dec 27, 2030
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Jan 22, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this trial is to evaluate whether treatment with pelabresib in combination with ruxolitinib leads to improved clinical outcomes compared to ruxolitinib alone in patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia myelofibrosis (PET-MF) who have not previously received Janus kinase (JAK) inhibitor therapy.
Conditions
- Primary Myelofibrosis (PMF)
- Post-polycythemia Vera Myelofibrosis (PPV-MF)
- Post-essential Thrombocythemia Myelofibrosis (PET-MF)
Interventions
PelabresibDrug
Pelabresib monohydrate tablets
RuxolitinibDrug
Ruxolitinib phosphate tablets
PlaceboDrug
Matches pelabresib
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Splenic Response (SVR35) by Central Radiology Reads at Week 24 in participants with baseline total symptom score (TSS) ≥ 25Time frame: Week 24
- Absolute change from baseline in total symptom score (TSS) at Week 24 in participants with baseline TSS ≥ 25Time frame: Baseline, Week 24
- Number of Participants with Splenic Response (SVR35) by Central Radiology Reads at Week 24 in participants with baseline TSS ≥ 15Time frame: Week 24
- Absolute change from baseline in total symptom score (TSS) at Week 24 in participants with baseline TSS ≥ 15Time frame: Baseline, Week 24
Locations
174 sites in 24 countries. Site status is shown where the registry gives one.
Rocky Mountain Cancer Centers
Denver, Colorado · Recruiting
Yale University School Of Medicine
New Haven, Connecticut · Recruiting
Florida Cancer Specialist South Reg
Fort Myers, Florida · Recruiting
The Anderson Family Cancer Institute
Jupiter, Florida · Recruiting
Miami NS Ins Baptist Health S FL
Miami, Florida · Recruiting
Orlando Health Clinical Trials
Orlando, Florida · Recruiting
Florida Cancer Specialists-North
St. Petersburg, Florida · Recruiting
Florida Cancer Specialists East
Stuart, Florida · Recruiting
Winship Cancer Institute of Emory University
Atlanta, Georgia · Recruiting
University of Chicago Hospital
Chicago, Illinois · Recruiting
Franciscan Health Indianapolis
Indianapolis, Indiana · Recruiting
American Oncology Partners PA Center for Cancer and Blood Disorders
Bethesda, Maryland · Recruiting
Michigan Med University of Michigan
Ann Arbor, Michigan · Recruiting
Summit Medical Group Oncology
Berkeley Heights, New Jersey · Recruiting
New York Oncology Hematology P C
Albany, New York · Recruiting
Columbia University Medical Center New York Presbyterian
New York, New York · Recruiting
Sanford Research USD Fargo
Fargo, North Dakota · Recruiting
The Ohio State University Comprehensive Cancer Center
Columbus, Ohio · Recruiting
Texas Oncology - Central South
Austin, Texas · Recruiting
Texas Oncology PA Dallas Presbyterian Hospital
Dallas, Texas · Recruiting
MD Anderson Cancer Center
Houston, Texas · Recruiting
SCRI Texas Oncology Northeast Texas
Tyler, Texas · Recruiting
Virginia Cancer Specialists
Fairfax, Virginia · Recruiting
Fred Hutch Cancer Research
Seattle, Washington · Recruiting
Hospital Italiano de Buenos Aires
CABA, Argentina · Recruiting
FUNDALEU
Capital Federal, Argentina · Recruiting
Hospital Privado de Cordoba
Córdoba, Argentina · Recruiting
Novartis Investigative Site
CABA, Buenos Aires, Argentina · Recruiting
Hospital de Clinicas Jose de San Martin
Buenos Aires, Buenos Aires F.D., Argentina · Recruiting
Novartis Investigative Site
Adelaide, South Australia, Australia · Recruiting
Novartis Investigative Site
Clayton, Victoria, Australia · Recruiting
Novartis Investigative Site
Graz, Austria · Recruiting
Novartis Investigative Site
Salzburg, Austria · Recruiting
Novartis Investigative Site
Sankt Pölten, Austria · Recruiting
Novartis Investigative Site
Vienna, Austria · Recruiting
Novartis Investigative Site
Roeselare, Belgium · Recruiting
Novartis Investigative Site
Woluwe-Saint-Lambert, Brussels Capital, Belgium · Recruiting
Novartis Investigative Site
Goiânia, Goiás, Brazil · Recruiting
Novartis Investigative Site
Curitiba, Paraná, Brazil · Recruiting
Grupo ELORA
Florianópolis, Santa Catarina, Brazil · Recruiting
Showing 40 of 174 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.